Principles and practice of HIV-protease inhibitor pharmacoenhancement (Q34459378)

2 August 2017

1 reference

title

Principles and practice of HIV-protease inhibitor pharmacoenhancement (English)

1 reference

2 August 2017

Moyle GJ

1

1 reference

2 August 2017

Back D

series ordinal

2

1 reference

2 August 2017

publication date

1 April 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

105-113

1 reference

Nelfinavir. A review of its therapeutic efficacy in HIV infection

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

A risk-benefit assessment of HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Crystalluria and urinary tract abnormalities associated with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Changes in renal function associated with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00063.X

10.1046/J.1468-1293.2001.00063.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference